In one aspect, the present disclosure provides targeted complement-activating molecules comprising a target-binding domain and a complement-activating serine protease effector domain. In some embodiments, the target-binding domain is derived from an antibody or an antigen-binding fragment thereof. Also provided are compositions and methods for treating cancer, autoimmune disease, or microbial infection, including bacterial, viral, fungal, or parasitic infection, using targeted complement-activating molecules.

The invention relates to generation and use of cellular and humoral responses for the prevention and treatment of P. gingivalis related conditions and diseases.

Provided is a novel cancer-treating agent which can be used as a novel choice for the treatment of cancer. Specifically provided are: a peptide that inhibits binding of ERAP1 polypeptide to PHB2 polypeptide, which comprises a binding site of the ERAP1 polypeptide to the PHB2 polypeptide, and a pharmaceutical composition comprising the peptide. In addition, provided is a method for screening a drug candidate for treating and/or preventing cancer using inhibition of the binding of the ERAP1 polypeptide to PP1α polypeptide, PKA polypeptide or PKB polypeptide as an index.

Devices, bandages, kits and methods are described that can control or regulate the mechanical environment of a wound to ameliorate scar and/or keloid formation. The mechanical environment of a wound includes stress, strain, and any combination of stress and strain. The control of a wound's mechanical environment can be active, passive, dynamic, or static. The devices are configured to be removably secured to a skin surface in proximity to the wound site and shield the wound from endogenous and/or exogenous stress.

A four-biomarker panel for diagnosis of chronic graft-versus-host disease (cGVHD) and methods of prognosing and/or diagnosing cGVHD using the biomarker panel are disclosed.

The invention relates generally to compositions and methods for detecting protease activity in a subject or a biological sample using activatable antibodies, and the use of these compositions and methods in a variety of diagnostic indications.

The disclosed technology relates to chemical entities for the detection of wounds, e.g., chronic wounds or infected wounds, including compositions, substrates, kits, dressing materials, and articles, and systems containing such compounds. The disclosed technology further relates to methods of using these compositions, kits and systems in diagnostic assays, and in the diagnosis and/or detection of chronic or infected wounds based on enzymatic action on specific moieties and/or reaction sites. The disclosed technology additionally relates to detection of pathogenic, e.g., bacterial and/or viral substances, such as enzymes and substrates, at the wound situs. Additional disclosure relates to methods of characterizing wounds based on expression of a plurality of markers and using such information to treat, manage, and follow-up patients suffering from chronic or infected wounds.

Methods, systems, kits, and other techniques and discoveries for the prediction, detection, monitoring, treatment, and general diagnosis and prognosis of Alzheimer's disease (AD) in subjects utilizing information obtained by detection of biomarkers and biomarker combinations present in the saliva of subjects afflicted with AD. Aspects of the invention may be implemented to detect, monitor, treat and diagnose subjects who are asymptomatic of AD early in the disease process. Other aspects of the invention may be implemented to identify and differentiate the level of severity of AD in a subject such as, for example, identification of mild AD in a subject who is completely asymptomatic of AD, differentiation of mild AD from moderate AD, and differentiation of moderate AD from severe AD.

The present invention relates to the quantification of various biomarkers, including MMP9 (Inflammatory marker), LOX (Lysyl oxidase), IL6 (Interleukin-6), TNFα (tumor necrosis factor alpha), VEGF (Vascular Endothelial Growth Factor) ICAM-1 (Intercellular Adhesion Molecule-1) in aqueous humor, vitreous humor, tear and serum of patients with ocular diseases. The invention further describes the role of biomarkers in the pathogenesis, progression of ocular diseases. Hence, the level of biomarkers serves as a diagnostic and/or prognostic marker in ocular diseases. The invention further relates to the use of multiple biomarkers that can be simultaneously used for testing various corneal and retinal diseases.

The present application provides compositions and methods for determining a disease or condition in a subject. The method comprises contacting a body fluid with a molecule comprising a reporter thereof and the reported is cleaved by an agent in the body fluid. Diseases and conditions that can be determined by the method are also described.